Rigel Pharmaceuticals
RIGL
103 hedge funds and large institutions have $282M invested in Rigel Pharmaceuticals in 2014 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 34 increasing their positions, 39 reducing their positions, and 20 closing their positions.
241% more call options, than puts
Call options by funds: $109K | Put options by funds: $32K
6% less capital invested
Capital invested by funds: $300M → $282M (-$18.1M)
6% less funds holding
Funds holding: 110 → 103 (-7)
13% less repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 39
35% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$5.72M |
| 2 |
DM
Deerfield Management
New York
|
+$4.66M |
| 3 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$2.09M |
| 4 |
SAM
Senzar Asset Management
New York
|
+$1.71M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$10M |
| 2 |
PC
Polar Capital
London,
United Kingdom
|
-$2.01M |
| 3 |
PC
PointState Capital
New York
|
-$1.94M |
| 4 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$1.81M |
| 5 |
Millennium Management
New York
|
-$1.65M |
RIGL Hedge Fund Activity: Q2 2014 in Review
103 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q2 2014, worth a combined $282M — down 6% from $300M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of RIGL and 13 opened new positions — a net loss of 7 holders — while 39 trimmed existing stakes and 34 added.
The largest buyer was Wellington Management Group, adding an estimated $5.72M. The largest seller was BVF Inc, exiting entirely with an estimated $10M sold.
- 103 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q2 2014, down from 110 in Q1 2014.
- Funds reported $282M of Rigel Pharmaceuticals stock for Q2 2014, down 6% quarter-over-quarter.
- 13 funds opened new Rigel Pharmaceuticals positions in Q2 2014 and 20 closed out, a net change of -7 holders.
- The largest Rigel Pharmaceuticals buyer in Q2 2014 was Wellington Management Group, an estimated $5.72M added.
- The largest Rigel Pharmaceuticals seller in Q2 2014 was BVF Inc, an estimated $10M sold.
Based on aggregated 13F filings for Q2 2014.